|
1
|
Wee JT, Ha TC, Loong SL and Qian CN: Is
nasopharyngeal cancer really a ‘Cantonese cancer’? Chin J Cancer.
29:517–526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ng WT, Lee MC, Hung WM, Choi CW, Lee KC,
Chan OS and Lee AW: Clinical outcomes and patterns of failure after
intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int
J Radiat Oncol. 79:420–428. 2011. View Article : Google Scholar
|
|
3
|
Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J,
Tan TW, Fong KW, Chua ET and Wee JT: Treatment of nasopharyngeal
carcinoma using intensity-modulated radiotherapy-the national
cancer centre singapore experience. Int J Radiat Oncol.
75:1481–1486. 2009. View Article : Google Scholar
|
|
4
|
Stoker SD, van Diessen JN, de Boer JP,
Karakullukcu B, Leemans CR and Tan IB: Current treatment options
for local residual nasopharyngeal carcinoma. Curr Treat Options
Oncol. 14:475–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee CK, Brown C, Gralla RJ, Hirsh V,
Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T and Zaatar A:
Impact of EGFR inhibitor in non-small cell lung cancer on
progression-free and overall survival: A meta-analysis. J Natl
Cancer I. 105:595–605. 2013. View Article : Google Scholar
|
|
6
|
Dahabreh IJ, Linardou H, Siannis F,
Fountzilas G and Murray S: Trastuzumab in the adjuvant treatment of
early-stage breast cancer: A systematic review and meta-analysis of
randomized controlled trials. Oncologist. 13:620–630. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
et al: Randomized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: The M77001 study
group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn
JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G Jr, et al:
Adaptation of international guidelines for metastatic colorectal
cancer: An asian consensus. Clin Colorectal Cancer. 13:145–155.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adachi T, Hinoi T, Egi H, Shimomura M and
Ohdan H: Oxaliplatin and molecular-targeted drug therapies improved
the overall survival in colorectal cancer patients with synchronous
peritoneal carcinomatosis undergoing incomplete cytoreductive
surgery. Surg Today. Aug 26–2014.Epub ahead of print.
|
|
11
|
Chua DT, Wei WI, Wong MP, Sham JS,
Nicholls J and Au GK: Phase II study of gefitinib for the treatment
of recurrent and metastatic nasopharyngeal carcinoma. Head Neck.
30:863–867. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma B, Hui EP, King A, To KF, Mo F, Leung
SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, et al: A phase II study of
patients with metastatic or locoregionally recurrent nasopharyngeal
carcinoma and evaluation of plasma Epstein-Barr virus DNA as a
biomarker of efficacy. Cancer Chemother Pharmacol. 62:59–64. 2008.
View Article : Google Scholar
|
|
13
|
Elser C, Siu LL, Winquist E, Agulnik M,
Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, et
al: Phase II trial of sorafenib in patients with recurrent or
metastatic squamous cell carcinoma of the head and neck or
nasopharyngeal carcinoma. J Clin Oncol. 25:3766–3773. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW,
Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, et al:
Multicenter, phase II study of cetuximab in combination with
carboplatin in patients with recurrent or metastatic nasopharyngeal
carcinoma. J Clin Oncol. 23:3568–3576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Banville D, Stocco R and Shen SH: Human
protein tyrosine phosphatase 1C (PTPN6) gene structure: Alternate
promoter usage and exon skipping generate multiple transcripts.
Genomics. 27:165–173. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Evren S, Wan S, Ma XZ, Fahim S, Mody N,
Sakac D, Jin T and Branch DR: Characterization of SHP-1 protein
tyrosine phosphatase transcripts, protein isoforms and phosphatase
activity in epithelial cancer cells. Genomics. 102:491–499. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng G, Cao R, Xue J, Li P, Zou Z, Huang J
and Ding Q: Increased expression of SHP-1 is associated with local
recurrence after radiotherapy in patients with nasopharyngeal
carcinoma. Radiol Oncol. 48:40–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng G, Cao RB, Li YH, Zou ZW, Huang J and
Ding Q: Alterations of cell cycle control proteins SHP-1/2, p16,
CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma
cells. Mol Med Rep. 10:1709–1716. 2014.PubMed/NCBI
|
|
19
|
Cao R, Ding Q, Li P, Xue J, Zou Z, Huang J
and Peng G: SHP1-mediated cell cycle redistribution inhibits
radiosensitivity of non-small cell lung cancer. Radiat Oncol.
8:1782013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li G, Qiu Y, Su Z, Ren S, Liu C, Tian Y
and Liu Y: Genome-wide analyses of radioresistance-associated miRNA
expression profile in nasopharyngeal carcinoma using next
generation deep sequencing. PloS One. 8:e844862013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li G, Liu Y, Su Z, Ren S, Zhu G, Tian Y
and Qiu Y: MicroRNA-324-3p regulates nasopharyngeal carcinoma
radioresistance by directly targeting WNT2B. Eur J Cancer.
49:2596–2607. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Pu J, Qi T, Qi M, Yang C, Li S,
Huang K, Zheng L and Tong Q: MicroRNA-145 inhibits the growth,
invasion, metastasis and angiogenesis of neuroblastoma cells
through targeting hypoxia-inducible factor 2 alpha. Oncogene.
33:387–397. 2014. View Article : Google Scholar
|
|
23
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar
|
|
24
|
Cheng G: Circulating miRNAs: Roles in
cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev.
81:75–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Gu X, Zhou M, Xiang J and Chen Z:
Serum microRNAs: A new diagnostic method for colorectal cancer.
Biomed Rep. 1:495–498. 2013.
|
|
26
|
Berger F and Reiser MF: Micro-RNAs as
potential new molecular biomarkers in oncology: Have they reached
relevance for the clinical imaging sciences? Theranostics.
3:943–952. 2013. View Article : Google Scholar
|
|
27
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duchaine TF and Slack FJ: RNA interference
and micro RNA-oriented therapy in cancer: rationales, promises, and
challenges. Curr Oncol. 16:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tagliaferri P, Rossi M, Di Martino MT,
Amodio N, Leone E, Gulla A, Neri A and Tassone P: Promises and
challenges of MicroRNA-based treatment of multiple myeloma. Curr
Cancer Drug Targets. 12:838–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Orang AV and Barzegari A: MicroRNAs in
colorectal cancer: from diagnosis to targeted therapy. Asian Pac J
Cancer Prev. 15:6989–6999. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Long Z, Wang B, Tao D, Huang Y and Tao Z:
Hypofractionated radiotherapy induces miR-34a expression and
enhances apoptosis in human nasopharyngeal carcinoma cells. Int J
Mol Med. 34:1388–1394. 2014.PubMed/NCBI
|
|
32
|
Li G, Wang Y, Liu Y, Su Z, Liu C, Ren S,
Deng T, Huang D, Tian Y and Qiu Y: miR-185-3p regulates
nasopharyngeal carcinoma radioresistance by targeting WNT2B in
vitro. Cancer Sci. 105:1560–1568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang C, Fang X, Li W, Shi Q, Wu L, Chen
X, Huang Z, Wu P, Wang Z and Liao Z: Influence of recombinant
lentiviral vector encoding miR-15a/16-1 in biological features of
human nasopharyngeal carcinoma CNE-2Z cells. Cancer Biother
Radiopharm. 29:422–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li XH, Qu JQ, Yi H, Zhang PF, Yi HM, Wan
XX, He QY, Ye X, Yuan L, Zhu JF, et al: Integrated analysis of
differential miRNA and mRNA expression profiles in human
radioresistant and radiosensitive nasopharyngeal carcinoma cells.
PLoS One. 9:e877672014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang JX, Qian D, Wang FW, Liao DZ, Wei
JH, Tong ZT, Fu J, Huang XX, Liao YJ and Deng HX: MicroRNA-29c
enhances the sensitivities of human nasopharyngeal carcinoma to
cisplatin-based chemotherapy and radiotherapy. Cancer Lett.
329:91–98. 2013. View Article : Google Scholar
|
|
36
|
Qu C, Liang Z, Huang J, Zhao R, Su C, Wang
S, Wang X, Zhang R, Lee MH and Yang H: MiR-205 determines the
radioresistance of human nasopharyngeal carcinoma by directly
targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen ZX, Sun AM, Chen Y, Liu Y, Zhan JF,
Chen LH and Yuan YW: Effects of radiosensitivity and X-ray dose on
miR-7 expression in nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue
Xue Bao. 30:1810–1812. 2010.In Chinese.
|
|
38
|
Tong L, Yuan Y and Wu S: Therapeutic
microRNAs targeting the NF-kappa B signaling circuits of cancers.
Adv Drug Deliv Rev. 81:1–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang T, Sun Q, Liu T, Chen J, Du S, Ren
C, Liao G and Yuan Y: MiR-451 increases radiosensitivity of
nasopharyngeal carcinoma cells by targeting ras-related protein 14
(RAB14). Tumor Biol. 35:12593–12599. 2014. View Article : Google Scholar
|
|
40
|
Gandhi NS, Tekade RK and Chougule MB:
Nanocarrier mediated delivery of siRNA/miRNA in combination with
chemotherapeutic agents for cancer therapy: current progress and
advances. J Control Release. 194:238–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Delibrias CC, Floettmann JE, Rowe M and
Fearon DT: Downregulated expression of SHP-1 in Burkitt lymphomas
and germinal center B lymphocytes. J Exp Med. 186:1575–1583. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oka T, Yoshino T, Hayashi K, Ohara N,
Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, et
al: Reduction of hematopoietic cell-specific tyrosine phosphatase
SHP-1 gene expression in natural killer cell lymphoma and various
types of lymphomas/leukemias: combination analysis with cDNA
expression array and tissue microarray. Am J Pathol. 159:1495–1505.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sato K, Horiuchi M, Yo R and Nakarai I: A
long survival case of small cell lung cancer synchronized with
renal cancer. Kyobu Geka. 44:251–253. 1991.In Japanese. PubMed/NCBI
|
|
44
|
Amin HM, Hoshino K, Yang H, Lin Q, Lai R
and Garcia-Manero G: Decreased expression level of SH2
domain-containing protein tyrosine phosphatase-1 (SHP-1) is
associated with progression of chronic myeloid leukaemia. J Pathol.
212:402–410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
López-Ruiz P, Rodriguez-Ubreva J, Cariaga
AE, Cortes MA and Colás B: SHP-1 in cell-cycle regulation.
Anticancer Agents Med Chem. 11:89–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
